НовостиBenzingaMorgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30 Morgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30 Benzinga 2026.11.10 17:01 (GMT+0) Открыть на Benzinga Другие новости